Changes in RANKL during the first two years after cART initiation in HIV-infected cART naïve adults

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Changes in RANKL during the first two years after cART initiation in HIV-infected cART naïve adults. / Mathiesen, Inger Hee Mabuza; Salem, Mohammad; Gerstoft, Jan; Gaardbo, Julie Christine; Obel, Niels; Pedersen, Court; Ullum, Henrik; Nielsen, Susanne Dam; Hansen, Ann-Brit Eg.

In: B M C Infectious Diseases, Vol. 17, 262, 11.04.2017.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Mathiesen, IHM, Salem, M, Gerstoft, J, Gaardbo, JC, Obel, N, Pedersen, C, Ullum, H, Nielsen, SD & Hansen, A-BE 2017, 'Changes in RANKL during the first two years after cART initiation in HIV-infected cART naïve adults', B M C Infectious Diseases, vol. 17, 262. https://doi.org/10.1186/s12879-017-2368-y

APA

Mathiesen, I. H. M., Salem, M., Gerstoft, J., Gaardbo, J. C., Obel, N., Pedersen, C., Ullum, H., Nielsen, S. D., & Hansen, A-B. E. (2017). Changes in RANKL during the first two years after cART initiation in HIV-infected cART naïve adults. B M C Infectious Diseases, 17, [262]. https://doi.org/10.1186/s12879-017-2368-y

Vancouver

Mathiesen IHM, Salem M, Gerstoft J, Gaardbo JC, Obel N, Pedersen C et al. Changes in RANKL during the first two years after cART initiation in HIV-infected cART naïve adults. B M C Infectious Diseases. 2017 Apr 11;17. 262. https://doi.org/10.1186/s12879-017-2368-y

Author

Mathiesen, Inger Hee Mabuza ; Salem, Mohammad ; Gerstoft, Jan ; Gaardbo, Julie Christine ; Obel, Niels ; Pedersen, Court ; Ullum, Henrik ; Nielsen, Susanne Dam ; Hansen, Ann-Brit Eg. / Changes in RANKL during the first two years after cART initiation in HIV-infected cART naïve adults. In: B M C Infectious Diseases. 2017 ; Vol. 17.

Bibtex

@article{a60734513c8e45b4b72047ffed1bddec,
title = "Changes in RANKL during the first two years after cART initiation in HIV-infected cART na{\"i}ve adults",
abstract = "BACKGROUND: By assessing the changes in concentration of soluble receptor activator of nuclear factor κ B ligand (RANKL) and osteoprotegrin (OPG) after initiation of combination antiretroviral therapy (cART) in treatment-na{\"i}ve HIV-infected patients we aimed to evaluate whether the initial accelerated bone loss could be mediated by increased soluble RANKL (sRANKL) levels associated with CD4+ T cell recovery.METHODS: We used multiplex immunoassays to determine sRANKL and OPG concentrations in plasma from 48 HIV patients at baseline and 12, 24, 48 and 96 weeks after cART initiation.RESULTS: Soluble RANKL changed significantly over time (overall p = 0.02) with 25% decrease (95% CI: -42 to -5) at week 24 compared to baseline and stabilized at a lower level thereafter. We found no correlation between CD4+ T cell count increment and changes in sRANKL or between percentage change in BMD and changes in sRANKL.CONCLUSION: In this study there was no indication that the accelerated bone loss after cART initiation was mediated by early changes in sRANKL due to CD4+ T cell recovery. Future studies should focus on the initial weeks after initiation of cART.TRIAL REGISTRATION: Clinical-Trial.gov . id NCT00135460 , August 25, 2005. The study was approved by the Danish Data Protection Agency, Danish Medicines Agency and Regional Ethics Committee.",
keywords = "Adult, Anti-HIV Agents, CD4-Positive T-Lymphocytes, Drug Therapy, Combination, Female, HIV Infections, Humans, Lymphocyte Count, Male, Middle Aged, RANK Ligand, Journal Article",
author = "Mathiesen, {Inger Hee Mabuza} and Mohammad Salem and Jan Gerstoft and Gaardbo, {Julie Christine} and Niels Obel and Court Pedersen and Henrik Ullum and Nielsen, {Susanne Dam} and Hansen, {Ann-Brit Eg}",
year = "2017",
month = apr,
day = "11",
doi = "10.1186/s12879-017-2368-y",
language = "English",
volume = "17",
journal = "B M C Infectious Diseases",
issn = "1471-2334",
publisher = "BioMed Central Ltd.",

}

RIS

TY - JOUR

T1 - Changes in RANKL during the first two years after cART initiation in HIV-infected cART naïve adults

AU - Mathiesen, Inger Hee Mabuza

AU - Salem, Mohammad

AU - Gerstoft, Jan

AU - Gaardbo, Julie Christine

AU - Obel, Niels

AU - Pedersen, Court

AU - Ullum, Henrik

AU - Nielsen, Susanne Dam

AU - Hansen, Ann-Brit Eg

PY - 2017/4/11

Y1 - 2017/4/11

N2 - BACKGROUND: By assessing the changes in concentration of soluble receptor activator of nuclear factor κ B ligand (RANKL) and osteoprotegrin (OPG) after initiation of combination antiretroviral therapy (cART) in treatment-naïve HIV-infected patients we aimed to evaluate whether the initial accelerated bone loss could be mediated by increased soluble RANKL (sRANKL) levels associated with CD4+ T cell recovery.METHODS: We used multiplex immunoassays to determine sRANKL and OPG concentrations in plasma from 48 HIV patients at baseline and 12, 24, 48 and 96 weeks after cART initiation.RESULTS: Soluble RANKL changed significantly over time (overall p = 0.02) with 25% decrease (95% CI: -42 to -5) at week 24 compared to baseline and stabilized at a lower level thereafter. We found no correlation between CD4+ T cell count increment and changes in sRANKL or between percentage change in BMD and changes in sRANKL.CONCLUSION: In this study there was no indication that the accelerated bone loss after cART initiation was mediated by early changes in sRANKL due to CD4+ T cell recovery. Future studies should focus on the initial weeks after initiation of cART.TRIAL REGISTRATION: Clinical-Trial.gov . id NCT00135460 , August 25, 2005. The study was approved by the Danish Data Protection Agency, Danish Medicines Agency and Regional Ethics Committee.

AB - BACKGROUND: By assessing the changes in concentration of soluble receptor activator of nuclear factor κ B ligand (RANKL) and osteoprotegrin (OPG) after initiation of combination antiretroviral therapy (cART) in treatment-naïve HIV-infected patients we aimed to evaluate whether the initial accelerated bone loss could be mediated by increased soluble RANKL (sRANKL) levels associated with CD4+ T cell recovery.METHODS: We used multiplex immunoassays to determine sRANKL and OPG concentrations in plasma from 48 HIV patients at baseline and 12, 24, 48 and 96 weeks after cART initiation.RESULTS: Soluble RANKL changed significantly over time (overall p = 0.02) with 25% decrease (95% CI: -42 to -5) at week 24 compared to baseline and stabilized at a lower level thereafter. We found no correlation between CD4+ T cell count increment and changes in sRANKL or between percentage change in BMD and changes in sRANKL.CONCLUSION: In this study there was no indication that the accelerated bone loss after cART initiation was mediated by early changes in sRANKL due to CD4+ T cell recovery. Future studies should focus on the initial weeks after initiation of cART.TRIAL REGISTRATION: Clinical-Trial.gov . id NCT00135460 , August 25, 2005. The study was approved by the Danish Data Protection Agency, Danish Medicines Agency and Regional Ethics Committee.

KW - Adult

KW - Anti-HIV Agents

KW - CD4-Positive T-Lymphocytes

KW - Drug Therapy, Combination

KW - Female

KW - HIV Infections

KW - Humans

KW - Lymphocyte Count

KW - Male

KW - Middle Aged

KW - RANK Ligand

KW - Journal Article

U2 - 10.1186/s12879-017-2368-y

DO - 10.1186/s12879-017-2368-y

M3 - Journal article

C2 - 28399815

VL - 17

JO - B M C Infectious Diseases

JF - B M C Infectious Diseases

SN - 1471-2334

M1 - 262

ER -

ID: 180569955